415 related articles for article (PubMed ID: 28881156)
1. Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods.
Smith TRF; Schultheis K; Broderick KE
Hum Vaccin Immunother; 2017 Nov; 13(11):2626-2629. PubMed ID: 28881156
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of mucosal and cellular immune response in mice by vaccination with respiratory syncytial virus DNA encapsulated with transfersome.
Xu J; Ding Y; Yang Y
Viral Immunol; 2008 Dec; 21(4):483-9. PubMed ID: 19115938
[TBL] [Abstract][Full Text] [Related]
3. Gene-based vaccine approaches for respiratory syncytial virus.
Loomis RJ; Johnson PR
Curr Top Microbiol Immunol; 2013; 372():307-24. PubMed ID: 24362696
[TBL] [Abstract][Full Text] [Related]
4. Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus.
Smith TRF; Schultheis K; Morrow MP; Kraynyak KA; McCoy JR; Yim KC; Muthumani K; Humeau L; Weiner DB; Sardesai NY; Broderick KE
Vaccine; 2017 May; 35(21):2840-2847. PubMed ID: 28413132
[TBL] [Abstract][Full Text] [Related]
5. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
[TBL] [Abstract][Full Text] [Related]
6. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS
Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001
[TBL] [Abstract][Full Text] [Related]
7. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
[TBL] [Abstract][Full Text] [Related]
8. Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency.
Farrag MA; Amer HM; Öhlschläger P; Hamad ME; Almajhdi FN
Hum Vaccin Immunother; 2017 Jul; 13(7):1586-1597. PubMed ID: 28272978
[TBL] [Abstract][Full Text] [Related]
9. Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease.
Hwang HS; Lee YT; Kim KH; Park S; Kwon YM; Lee Y; Ko EJ; Jung YJ; Lee JS; Kim YJ; Lee YN; Kim MC; Cho M; Kang SM
Virology; 2016 Jul; 494():215-24. PubMed ID: 27123586
[TBL] [Abstract][Full Text] [Related]
10. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
[TBL] [Abstract][Full Text] [Related]
11. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
[TBL] [Abstract][Full Text] [Related]
12. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
[TBL] [Abstract][Full Text] [Related]
13. Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2.
Zeng R; Qi X; Gong W; Mei X; Wei L; Ma C; Yin X
Vaccine; 2007 Oct; 25(42):7422-8. PubMed ID: 17850930
[TBL] [Abstract][Full Text] [Related]
14. Vaccines against human respiratory syncytial virus in clinical trials, where are we now?
Rossey I; Saelens X
Expert Rev Vaccines; 2019 Oct; 18(10):1053-1067. PubMed ID: 31587585
[No Abstract] [Full Text] [Related]
15. Recombinant baculovirus-based vaccine expressing M2 protein induces protective CD8
Lee JY; Chang J
J Microbiol; 2017 Nov; 55(11):900-908. PubMed ID: 29076066
[TBL] [Abstract][Full Text] [Related]
16. Naked DNA immunization with full-length attachment gene of human respiratory syncytial virus induces safe and protective immune response.
Hamad ME; Amer HM; Farrag MA; Osman AH; Almajhdi FN
Acta Virol; 2018; 62(2):137-146. PubMed ID: 29895154
[TBL] [Abstract][Full Text] [Related]
17. Advances in and the potential of vaccines for respiratory syncytial virus.
Jorquera PA; Oakley KE; Tripp RA
Expert Rev Respir Med; 2013 Aug; 7(4):411-27. PubMed ID: 23964629
[TBL] [Abstract][Full Text] [Related]
18. Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children.
Buchholz UJ; Cunningham CK; Muresan P; Gnanashanmugam D; Sato P; Siberry GK; Rexroad V; Valentine M; Perlowski C; Schappell E; Thumar B; Luongo C; Barr E; Aziz M; Yogev R; Spector SA; Collins PL; McFarland EJ; Karron RA;
J Infect Dis; 2018 Apr; 217(9):1338-1346. PubMed ID: 29509929
[TBL] [Abstract][Full Text] [Related]
19. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
[TBL] [Abstract][Full Text] [Related]
20. Vaccines against respiratory syncytial virus: The time has finally come.
Graham BS
Vaccine; 2016 Jun; 34(30):3535-41. PubMed ID: 27182820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
